ONCO
OnconetixFNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-07-22
Current thesis
Composite grade F from latest DB weights. Momentum 6.7 / Value 58.9
Posture
Defensive
Lead driver
Value
What changed
Value remains the lead driver in the composite, 7D delta +0.2.
What can break
Mixed signals. Wait for cleaner trend confirmation.
Momentum
7
Value
59
Sentiment
N/A
Setup hits (3d)
0 · Net Neutral
AI TargetsBase - · Bull - · Bear -
Data freshness
Prices
As of 2026-07-22
Fundamentals
As of 2026-07-21 • Vendor: Data Vendor v1
Scores
As of 2026-07-22 • Model: HYBRID_IC_RP
AI Memo
Unavailable: No memo yet
Investment thesisAs of 2026-07-22
Investment thesis
As of 2026-07-22
Supporting evidence
What
Grade F · Defensive
Confidence Medium · Net Neutral
Why
Momentum7 · Δ7d -
Value59 · Δ7d +0.2
SentimentN/A · Δ7d -
So what
Weak posture (Net Neutral). Prioritize risk control and patience.
Lead driver: Value · See fundamentals
Momentum
7
40% active weight
Current posture
7d trendTrend unavailable
Trend unavailable
Δ7d
-
Δ21d
-
Value
59
60% active weight
Current posture
7d trendFlat
Δ7d
+0.2
Δ21d
+17.7
Sentiment
N/A
Coverage pending
No current score
7d trendTrend unavailable
Trend unavailable
Δ7d
-
Δ21d
-
Why this grade
Composite grade F. Momentum 6.7 / Value 58.9
Fundamentals (TTM)As of 2026-07-21
Fundamentals (TTM)
As of 2026-07-21
Market Cap
$3.28M
Beta
3.45
Shares Out
3.69M
P/E (TTM) · Derived
-0.0
P/S (TTM)
2.11
P/FCF (TTM) · Derived
-0.00
Rev YoY
-78.9%
EPS YoY
-97.0%
Gross Margin
+79.6%
Op Margin
-4192.2%
Net Debt
-$5.17M
Current Ratio
1.41
As of 2026-07-22 • Updated nightlySource: Internal modelMethodology